Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Oxycodone is a semi-synthetic opioid analgesic, derived from thebaine, used for the management of moderate to severe pain when non-opioid alternatives are inadequate. It acts as a full agonist at mu-opioid receptors (primary pharmacological target) in the brain and spinal cord and exerts analgesic, sedative, anxiolytic, and antitussive effects. Oxycodone is highly addictive, with potential for misuse, dependence, and life-threatening respiratory depression. Its safety profile requires strict medical oversight, and it is commonly formulated as hydrochloride salt for oral administration, sometimes in combination with non-opioid analgesics such as acetaminophen or aspirin.
Full agonist at mu-opioid receptor Partial agonist at kappa- and delta-opioid receptors Inhibits pain signaling in the CNS
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Oxycodone.